Literature DB >> 15210523

Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.

Padraig E O'Suilleabhain1, Victor Sung, Carlos Hernandez, Laura Lacritz, Richard B Dewey, Teodoro Bottiglieri, Ramon Diaz-Arrastia.   

Abstract

BACKGROUND: An elevated plasma homocysteine (Hcy) level has been prospectively associated with an increased risk of vascular and degenerative dementias. An Hcy elevation is prevalent in patients with Parkinson disease (PD) in part because levodopa metabolism produces Hcy. The clinical relevance of an elevated Hcy level in patients with PD is unknown.
OBJECTIVE: To determine if hyperhomocysteinemia in patients with PD is associated with depression or with cognitive or physical impairments.
DESIGN: Ninety-seven people with a mean (SD) PD duration of 3.6 (1.6) years completed the Beck Depression Inventory, a battery of 11 cognitive tests, and the motor and function components of the Unified Parkinson's Disease Rating Scale. Normalized scores for the affective, cognitive, and physical measures were compared between those with a normal Hcy level (n = 66) and those with hyperhomocysteinemia (n = 31) (Hcy level, >1.89 mg/L [>14 micro mol/L]), controlling for age, sex, disease duration, and treatment.
RESULTS: Subjects with an elevated Hcy level were slightly older (68 vs 62 years), but had similar plasma concentrations of vitamin B(12) and folate. Hyperhomocysteinemic patients were more depressed (P =.02) and had worse cognition (P<.01), but the physical measure did not differ.
CONCLUSIONS: Patients with PD and hyperhomocysteinemia are more likely to be depressed and to perform worse on neuropsychometric tasks compared with normohomocysteinemic patients. Further research is warranted to see if hyperhomocysteinemia is a reversible risk factor for neuropsychiatric burden in patients with PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210523     DOI: 10.1001/archneur.61.6.865

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  27 in total

1.  Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.

Authors:  Thomas Müller; Constanze Jugel; Reinhard Ehret; Georg Ebersbach; Gunar Bengel; Siegfried Muhlack; Fabian Klostermann
Journal:  J Neural Transm (Vienna)       Date:  2011-02-27       Impact factor: 3.575

2.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

3.  Homocysteine and cognitive function in Parkinson's disease.

Authors:  Nicole Licking; Charles Murchison; Brenna Cholerton; Cyrus P Zabetian; Shu-Ching Hu; Thomas J Montine; Amie L Peterson-Hiller; Kathryn A Chung; Karen Edwards; James B Leverenz; Joseph F Quinn
Journal:  Parkinsonism Relat Disord       Date:  2017-08-09       Impact factor: 4.891

Review 4.  Homocysteine imbalance: a pathological metabolic marker.

Authors:  Kevin L Schalinske; Anne L Smazal
Journal:  Adv Nutr       Date:  2012-11-01       Impact factor: 8.701

Review 5.  What can biomarkers tell us about cognition in Parkinson's disease?

Authors:  Brit Mollenhauer; Lynn Rochester; Alice Chen-Plotkin; David Brooks
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 6.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

7.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

8.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Authors:  Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

9.  Peripheral COMT inhibition prevents levodopa associated homocysteine increase.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2009-08-06       Impact factor: 3.575

10.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.